
Sign up to save your podcasts
Or
Joining us for this episode was Mr. Ken Mariash, the CEO at Sinaptica Therapeutics. For over 20 years Ken has been leading & growing new business ventures on both the 'Buy Side' and the 'Build Side.' He started his career in management consulting at Charles River Associates then jumped to industry at CLS, then Baxter BioScience (acquired by Takeda) and then Boston Scientific with leadership roles in marketing, strategy & corporate development. Ken holds degrees in both Biochemistry & Business Economics from Brown University.
Today, Ken is leading the team at Sinaptica to advance their personalized closed-loop neuromodulation therapy for Alzheimers which has generated unprecedented Phase 2 sham-controlled clinical data that was recently published in the Oxford journal, 'Brain.' Sinaptica has FDA Breakthrough status for its novel proprietary approach which combines rTMS, EEG, and Neuronavigation with a sophisticated ML-derived personalization engine based on a novel brain target--the precuneus, the central hub of the Default Mode Network, a brain network involved in episodic memory. The company has completed all clinicals to date with non-dilutive funding and is now in-process of obtaining financing to complete the clinical product (SinaptiStim-AD) ** and prepare to initiate a pivotal study in one year's time.
Some of the major highlights we discussed:
-How Ken's upbringing shaped his early & future career days
-Pivotal roles that were instrumental in Ken's career development to becoming a CEO
-How Ken manages stress, especially during difficult times
-Ken's perspective on the toughest part of being a CEO
-Career advice for others coming up behind him
...and so much more
Key Takeaways:
Find Ken Mariash on LinkedIn:
https://www.linkedin.com/in/kenmariash/
Sinaptica Therapeutics on the web:
https://sinapticatx.com/
Note: (SinaptiStim is a trade mark of Sinaptica Therapeutics)
Joining us for this episode was Mr. Ken Mariash, the CEO at Sinaptica Therapeutics. For over 20 years Ken has been leading & growing new business ventures on both the 'Buy Side' and the 'Build Side.' He started his career in management consulting at Charles River Associates then jumped to industry at CLS, then Baxter BioScience (acquired by Takeda) and then Boston Scientific with leadership roles in marketing, strategy & corporate development. Ken holds degrees in both Biochemistry & Business Economics from Brown University.
Today, Ken is leading the team at Sinaptica to advance their personalized closed-loop neuromodulation therapy for Alzheimers which has generated unprecedented Phase 2 sham-controlled clinical data that was recently published in the Oxford journal, 'Brain.' Sinaptica has FDA Breakthrough status for its novel proprietary approach which combines rTMS, EEG, and Neuronavigation with a sophisticated ML-derived personalization engine based on a novel brain target--the precuneus, the central hub of the Default Mode Network, a brain network involved in episodic memory. The company has completed all clinicals to date with non-dilutive funding and is now in-process of obtaining financing to complete the clinical product (SinaptiStim-AD) ** and prepare to initiate a pivotal study in one year's time.
Some of the major highlights we discussed:
-How Ken's upbringing shaped his early & future career days
-Pivotal roles that were instrumental in Ken's career development to becoming a CEO
-How Ken manages stress, especially during difficult times
-Ken's perspective on the toughest part of being a CEO
-Career advice for others coming up behind him
...and so much more
Key Takeaways:
Find Ken Mariash on LinkedIn:
https://www.linkedin.com/in/kenmariash/
Sinaptica Therapeutics on the web:
https://sinapticatx.com/
Note: (SinaptiStim is a trade mark of Sinaptica Therapeutics)